Immunotherapy of liver cancer with hepcortespenlisimut-L: open-label Phase II clinical study in patients with advanced HCC

od Tarakanovskaya, Marina G, Chinburen, Jigjidsuren, Purevsuren, Genden, Munkhzaya, Chogsom, Batchuluun, Purev, Bat-Ireedui, Purev, Dandii, Dorjiin, Oyungerel, Dandii, Kutsyna, Galyna A, Bain, Allen I, Jirathitikal, Vichai, Bourinbaiar, Aldar S
izdano v J Immunother Cancer (2015)

Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

od Tarakanovskaya, Marina G, Chinburen, Jigjidsuren, Batchuluun, Purev, Munkhzaya, Chogsom, Purevsuren, Genden, Dandii, Dorjiin, Hulan, Tsogkhuu, Oyungerel, Dandii, Kutsyna, Galyna A, Reid, Alan A, Borisova, Vika, Bain, Allen I, Jirathitikal, Vichai, Bourinbaiar, Aldar S
izdano v J Hepatocell Carcinoma (2017)